The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia
Abstract
BACKGROUND: Hypertension and cognitive impairment are prevalent in older people. It is known that hypertension is a direct risk factor for vascular dementia and recent studies have suggested hypertension also impacts upon prevalence of Alzheimer's disease. The question is therefore whether treatment of hypertension lowers the rate of cognitive decline. OBJECTIVES: To assess the effects of blood pressure lowering treatments for the prevention of dementia and cognitive decline in patients with hypertension but no history of cerebrovascular disease. SEARCH STRATEGY: The trials were identified through a search of CDCIG's Specialised Register, CENTRAL, MEDLINE, EMBASE, PsycINFO and CINAHL on 27 April 2005. SELECTION CRITERIA: Randomized, double-blind, placebo controlled trials in which pharmacological or non-pharmacological interventions to lower blood pressure were given for at least six months. DATA COLLECTION AND ANALYSIS: Two independent reviewers assessed trial quality and extracted data. The following outcomes were assessed: incidence of dementia, cognitive change from baseline, blood pressure level, incidence and severity of side effects and quality of life. MAIN RESULTS: Three trials including 12,091 hypertensive subjects were identified. Average age was 72.8 years. Participants were recruited from industrialised countries. Mean blood pressure at entry across the studies was 170/84 mmHg. All trials instituted a stepped care approach to hypertension treatment, starting with a calcium-channel blocker, a diuretic or an angiotensin receptor blocker. The combined result of the three trials reporting incidence of dementia indicated no significant difference between treatment and placebo (Odds Ratio (OR) = 0.89, 95% CI 0.69, 1.16). Blood pressure reduction resulted in a 11% relative risk reduction of dementia in patients with no prior cerebrovascular disease but this effect was not statistically significant (p = 0.38) and there was considerable heterogeneity between the trials. The combined results from the two trials reporting change in Mini Mental State Examination (MMSE) did not indicate a benefit from treatment (Weighted Mean Difference (WMD) = 0.10, 95% CI -0.03, 0.23). Both systolic and diastolic blood pressure levels were reduced significantly in the two trials assessing this outcome (WMD = -7.53, 95% CI -8.28, -6.77 for systolic blood pressure, WMD = -3.87, 95% CI -4.25, -3.50 for diastolic blood pressure). Two trials reported adverse effects requiring discontinuation of treatment and the combined results indicated a significant benefit from placebo (OR = 1.18, 95% CI 1.06, 1.30). When analysed separately, however, more patients on placebo in SCOPE were likely to discontinue treatment due to side effects; the converse was true in SHEP 1991. Quality of life data could not be analysed in the three studies. There was difficulty with the control group in this review as many of the control subjects received antihypertensive treatment because their blood pressures exceeded pre-set values. In most cases the study became a comparison between the study drug against a usual antihypertensive regimen. AUTHORS' CONCLUSIONS: There was no convincing evidence from the trials identified that blood pressure lowering prevents the development of dementia or cognitive impairment in hypertensive patients with no apparent prior cerebrovascular disease. There were significant problems identified with analysing the data, however, due to the number of patients lost to follow-up and the number of placebo patients given active treatment. This introduced bias. More robust results may be obtained by analysing one year data to reduce differential drop-out or by conducting a meta-analysis using individual patient data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Staessen, J. A., Fagard, R., Thijs, L., Celis, H., Arabidze, G. G., Birkenhäger, W. H., Bulpitt, C. J., de Leeuw, P. W., Dollery, C. T., Fletcher, A. E., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(97)05381-6 · Cited by 2,989
15-year longitudinal study of blood pressure and dementia
Skoog, I., Nilsson, L., Persson, G., Lernfelt, B., Landahl, S., Palmertz, B., Andreasson, L.-A., Odén, A., & Svanborg, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90608-x · Cited by 1,726
Forette, F. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.18.2046 · Cited by 898
Bias in treatment assignment in controlled clinical trials
Chalmers, T. C., Celano, P., Sacks, H. S., & Smith, H. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312013092204 · Cited by 864
Hypertension Is Related to Cognitive Impairment: A 20-Year Follow-up of 999 Men
Kilander, L., Nyman, H., Boberg, M., Hansson, L., & Lithell, H. (1998) · Hypertension · doi:10.1161/01.hyp.31.3.780 · Cited by 630
Antihypertensive drugs and incidence of dementia: the Rotterdam Study
in’t Veld, B. A., Ruitenberg, A., Hofman, A., Stricker, B. H. C., & Breteler, M. M. B. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00241-4 · Cited by 254
Applegate, W. B. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420190047006 · Cited by 193
Lithell, H., Hansson, L., Skoog, I., Elmfeldt, D., Hofman, A., Olofsson, B., Trenkwalder, P., & Zanchetti, A. (2004) · Journal of Hypertension · doi:10.1097/01.hjh.0000133730.47372.4c · Cited by 104
Research works printed but not linked: 55
- Degl'Innocenti, 2004, Health-related quality of life during treatment of elderly patients with hypertension: results from the Study on COgnition and Prognosis in the Elderly (SCOPE), Journal of Human Hypertension, 18, 239, 10.1038/sj.jhh.1001657 · DOI
- Lithell, 2003, The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomised double-blind intervention trial, Journal of Hypertension, 21, 875, 10.1097/00004872-200305000-00011 · DOI · Paper page
- Papademetriou, 2004, Stroke Prevention With the Angiotension II Type-1 Receptor Blocker Candesartan in Elderly Patients With Isolated Systolic Hypertension. The Study on Cognition and Prognosis in the Elderly (SCOPE), Journal of the American College of Cardiology, 44, 1175
- Bari, 2001, Dementia and Disability Outcomes in Large Hypertension Trials: Lessons Learned from the Systolic Hypertension in the Elderly Program (SHEP) Trial, American Journal of Epidemiology, 153, 72, 10.1093/aje/153.1.72 · DOI · Paper page
- 1991, Prevention of Stroke by Antihypertensive Drug Treatment in Older Persons With Isolated Systolic Hypertension. Final Results of the Systolic Hypertension in the Elderly Program (SHEP), JAMA, 265, 3255, 10.1001/jama.1991.03460240051027 · DOI · Paper page
- 1988, Rationale and Design of a Randomized Clinical Trial on Prevention of Stroke in Isolated Systolic Hypertension, Journal of Clinical Epidemiology, 41, 1197, 10.1016/0895-4356(88)90024-8 · DOI
- Fletcher, 2002, Quality of life on randomised treatment for isolated hypertension: results from the Syst-Eur Trial, Journal of Hypertension, 20, 2069, 10.1097/00004872-200210000-00028 · DOI
- Fletcher, 1988, Quality of life of elderly patients with isolated systolic hypertension: baseline data from the Syst-Eur Trial, Journal of Hypertension, 16, 1117, 10.1097/00004872-199816080-00006 · DOI
- Forette, 1998, Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) Trial, Lancet, 352, 1347, 10.1016/S0140-6736(98)03086-4 · DOI · Paper page
- Forette, 2000, Reduction of dementia by calcium-antagonist-based antihypertensive treatment, European Heart Journal Supplements, 2, D17
- 2003, Diuretic Versus Alpha-Blocker as First-Step Antihypertensive Therapy. Final Results From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), Hypertension, 42, 239, 10.1161/01.HYP.0000086521.95630.5A · DOI · Paper page
- Dahlof, 2005, Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial, Lancet, 366, 895, 10.1016/S0140-6736(05)67185-1 · DOI · Paper page
- Black, 2001, One-Year Study of Felodipine or Placebo for Stage 1 Isolated Systolic Hypertension, Hypertension, 38, 1118, 10.1161/hy1101.095000 · DOI
- Elias, 1993, Untreated Blood Pressure Level is Inversely Related to Cognitive Functioning: The Framingham Study, American Journal of Epidemiology, 138, 353, 10.1093/oxfordjournals.aje.a116868 · DOI · Paper page
- Farmer, 1987, Blood Pressure and Cognitive Performance. The Framingham Study, American Journal of Epidemiology, 126, 1103, 10.1093/oxfordjournals.aje.a114749 · DOI · Paper page
- Launer, 1995, The Association Between Midlife Blood Pressure Levels and Late-Life Cognitive Function. The Honolulu-Asia Aging Study, JAMA, 274, 1846, 10.1001/jama.1995.03530230032026 · DOI · Paper page
- Syme, 1975, Epidemiologic Studies of Coronary Heart Disease and Stroke in Japanese Men Living in Japan, Hawaii and California: Introduction, American Journal of Epidemiology, 102, 477, 10.1093/oxfordjournals.aje.a112185 · DOI
- Starr, 1996, The Effects of Antihypertensive Treatment on Cognitive Function: Results from the HOPE Study, Journal of the American Geriatric Society, 44, 411, 10.1111/j.1532-5415.1996.tb06412.x · DOI
- Hsieh, 2003, Efficacy and Tolerability of Oral Stevioside in Patients with Mild Essential Hypertension: A Two-Year, Randomised, Placebo-Controlled Study, Clinical Therapeutics, 25, 2797, 10.1016/S0149-2918(03)80334-X · DOI · Paper page
- Amir, 1994, Does the Combination of ACE Inhibitor and Calcium Antagonist Control Hypertension and Improve Quality of Life? The LOMIR-MCT-IL Study Experience, Blood Pressure, 3(Suppl 1), 40
- Bar-On, 1993, Reexamining the Quality of Life of Hypertensive Patients. A New Self-Structured Measure, American Journal of Hypertension, 6, 62S, 10.1093/ajh/6.3.62S · DOI
- Yodfat, 1993, A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Isradipine and Methyldopa as Monotherapy or in Combination With Captopril in the Treatment of Hypertension, American Journal of Hypertension, 6, 57S, 10.1093/ajh/6.3.57S · DOI
- Peart, 1987, Results of MRC (UK) trial of drug therapy for mild hypertension, Clin Invest Med, 10, 616
- Prince, 1996, A longitudinal study of factors predicting change in cognitive test scores over time, in an older hypertensive population, Psychological Medicine, 26, 555, 10.1017/S0033291700035637 · DOI
- Prince, 1996, Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's treatment trial of hypertension in older adults, BMJ, 312, 801, 10.1136/bmj.312.7034.801 · DOI · Paper page
- Murray, 2002, Preservation of Cognitive Function With Antihypertensive Medications: A Longitudinal Analysis of a Community-Based Sample of African Americans Preservation of Cognitive Function With Antihypertensive Medications: A Longitudinal Analysis of a Community-Based Sample of African Americans, Archives of Internal Medicine, 162, 2090, 10.1001/archinte.162.18.2090 · DOI
- 2003, Effects of Blood Pressure Lowering With Perindopril and Indapamide Therapy on Dementia and Cognitive Decline in Patients With Cerebrovascular Disease, Arch Intern Med, 163, 1069, 10.1001/archinte.163.9.1069 · DOI · Paper page
- Richards, 2000, The Association Between Vascular Risk Factor-Mediating Medications and Cognition and Dementia Diagnosis in a Community-Based Sample of African-Americans, Journal of American Geriatrics Society, 48, 1035, 10.1111/j.1532-5415.2000.tb04777.x · DOI
- Hofman, 1997, Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study, The Lancet, 349, 151, 10.1016/S0140-6736(96)09328-2 · DOI · Paper page
- Dahlof, 1991, Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP Hypertension), Lancet, 338, 1281, 10.1016/0140-6736(91)92589-T · DOI · Paper page
- Liu, 1998, Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension, Journal of Hypertension, 16, 1823, 10.1097/00004872-199816120-00016 · DOI · Paper page
- Julius, 2004, Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial, Lancet, 363, 2022, 10.1016/S0140-6736(04)16451-9 · DOI · Paper page
- Amenta, 2002, Protective effect of anti-hypertensive treatment on cognitive function in essential hypertension: Analysis of published clinical data, Journal of the Neurological Sciences, 203- 204, 147-151, 10.1016/S0022-510X(02)00281-2 · DOI
- Amery, 1991, Syst-Eur. A multicentre trial on the treatment of isolated systolic hypertension in the elderly: Objectives, protocol, and organization., Aging Clin Exp Res, 3, 287, 10.1007/BF03324024 · DOI
- 1987, Diagnostic and Statistical Manual of Mental Disorders
- Bari, 2001, Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in the elderly program (SHEP) trial, American Journal of Epidemiology, 153, 72, 10.1093/aje/153.1.72 · DOI · Paper page
- Elias, 1993, Untreated blood pressure is inversely related to cognitive functioning: the Framingham Study, J of Epidemiol, 138, 352
- Farmer, 1987, Blood pressure and cognitive performance: the Framingham Study, Am J Epidemiol, 126, 1103, 10.1093/oxfordjournals.aje.a114749 · DOI · Paper page
- Forette, 1998, Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial, Lancet, 352, 1347, 10.1016/S0140-6736(98)03086-4 · DOI · Paper page
- Kilander, 1998, Hypertension is related to cognitive impairment, Hypertension, 31, 780, 10.1161/01.HYP.31.3.780 · DOI · Paper page
- McKhann, 1984, Clinical Diagnosis of Alzheimer’s Disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease, Neurology, 4, 939, 10.1212/WNL.34.7.939 · DOI · Paper page
- Mulrow, 1997, Cochrane Collaboration Handbook, The Cochrane Library [database on disc and CDROM ], Issue 1
- Prince, 1996, A longitudinal study of factors predicting change in cognitive test scores over time, in an older hypertensive population, Psychological Medicine, 26, 555, 10.1017/S0033291700035637 · DOI
- Qui, 2005, The age-dependent relation of blood pressure to cognitive function and dementia, Lancet Neurology, 4, 487, 10.1016/S1474-4422(05)70141-1 · DOI · Paper page
- Ratnasabapathy, 2003, Blood pressure lowering interventions for preventing dementia in patients with cerebrovascular disease (Protocol), The Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004130 · doi:10.1002/14651858.cd004130
- Schulz, 1995, Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials, JAMA, 273, 408, 10.1001/jama.1995.03520290060030 · DOI
- Skoog, 1996, 15 year longitudinal study of blood pressure and dementia, Lancet, 347, 1141, 10.1016/S0140-6736(96)90608-X · DOI · Paper page
- Starr, 1992, Senile hypertension and cognitive impairment: an overview, Journal of Hypertension, 10, S31
- Starr, 1996, The effects of antihypertensive treatment on cognitive function: Results from the HOPE study, Journal of the American Geriatric Society, 44, 411, 10.1111/j.1532-5415.1996.tb06412.x · DOI
- Stewart, 1993, Meta-analysis of the literature or of individual patient data: is there a difference?, Lancet, 341, 418, 10.1016/0140-6736(93)93004-K · DOI · Paper page
- Stewart, 1995, Practical methodology of meta-analyses (overviews) using update individual patient data, Stat Med, 14, 2057, 10.1002/sim.4780141902 · DOI · Paper page
- Tiernay, 2000, Is there a bias in the publication of individual patient data meta-analysis?, Int J Technol Assess Health Care, 16, 657, 10.1017/S0266462300101217 · DOI
- Vale, 2002, Effects of adjusting for censoring on meta-analyses of time-to-event outcomes, Int J Epidemiol, 31, 107, 10.1093/ije/31.1.107 · DOI
- Dujin, 1997, Atherosclerosis, apolipoprotein E and prevalence of dementia and Alzheimer's disease in the Rotterdam Study, Lancet, 349, 151, 10.1016/S0140-6736(96)09328-2 · DOI · Paper page
- 1992, The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines
Cited by
Gorelick, P. B., Scuteri, A., Black, S. E., DeCarli, C., Greenberg, S. M., Iadecola, C., Launer, L. J., Laurent, S., Lopez, O. L., Nyenhuis, D., et al. (2011) · Stroke · doi:10.1161/str.0b013e3182299496 · Cited by 3,811
Baumgart, M., Snyder, H. M., Carrillo, M. C., Fazio, S., Kim, H., & Johns, H. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.05.016 · Cited by 1,660
Peters, R., Beckett, N., Forette, F., Tuomilehto, J., Clarke, R., Ritchie, C., Waldman, A., Walton, I., Poulter, R., Ma, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70143-1 · Cited by 770
Iadecola, C., Yaffe, K., Biller, J., Bratzke, L. C., Faraci, F. M., Gorelick, P. B., Gulati, M., Kamel, H., Knopman, D. S., Launer, L. J., et al. (2016) · Hypertension · doi:10.1161/hyp.0000000000000053 · Cited by 746
Rothwell, P. M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60309-1 · Cited by 702
Metadata
- Authors
- McGuinness, B., Todd, S., Passmore, P., & Bullock, R.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2006-04-19
- Issue
- 2
- Pages
- CD004034-CD004034
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W1555463606
- Cited by
- 173
- References
- 9
- Type
- reference entry
- Language
- en
- Update notices
- new_version (2009-10-07)
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. https://app.cochat.ai/papers/10.1002/14651858.cd004034.pub2
- The paper
- McGuinness, B., Todd, S., Passmore, P., & Bullock, R. (2006). Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd004034.pub2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.